ARTICLE | Company News

No advisory panel meeting planned for Rigel’s fostamatinib

October 2, 2017 5:47 PM UTC

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) was up $0.83 (33%) to $3.37 on Monday after saying FDA does not plan to hold an Oncology Drugs Advisory Committee meeting to discuss an NDA for Tavalisse fostamatinib to treat chronic or persistent idiopathic thrombocytopenic purpura (ITP). The candidate's PDUFA date is April 17, 2018...

BCIQ Company Profiles

Rigel Pharmaceuticals Inc.

BCIQ Target Profiles

Spleen tyrosine kinase (SYK)